GlassScriptPhysician profile
John P Miskovsky
NPI 1497743330
$2,244.56
in general payments reported to CMS, 2019-2025
22 companies · $68.71 in 2025
The $68.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $327 · 2021: $185 · 2022: $626 · 2023: $164 · 2024: $333 · 2025: $68.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $245.22 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.97 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.88 | 2020-2024 | Lifevest |
| Stryker Corporation | $171.28 | 2019 | |
| Exact Sciences Corporation | $165.72 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $125.29 | 2021-2022 | |
| Janssen Biotech, INC. | $125.00 | 2019 | |
| Radius Health, INC. | $124.79 | 2019 | |
| Ferring Pharmaceuticals INC. | $123.68 | 2023 | Rebyota |
| Bayer Healthcare Pharmaceuticals INC. | $117.39 | 2022 | |
| Phathom Pharmaceuticals, INC. | $103.63 | 2024 | Voquezna |
| Allergan, INC. | $101.96 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.60 | 2022 | |
| Gramercy Extremity Orthopedics LLC | $77.86 | 2019 | |
| Novo Nordisk INC | $40.86 | 2024 | Ozempic, Rybelsus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.60 | 2023-2025 | Repatha, Repatha |
| Abbvie INC. | $28.08 | 2021 | |
| Lilly USA, LLC | $26.02 | 2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $23.57 | 2023 | Lokelma |
| Shire North American Group INC | $21.60 | 2019 | |
| Opko Pharmaceuticals, LLC | $20.52 | 2019 | |
| Pfizer INC. | $19.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Miskovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.